



Post-ASCO mCRC Academy

Beyond RAS: Navigating Precision Pathways in mCRC

Date: July 17th (Thu.)

Time: 19:00-20:30



Time	Topic	Speaker	Moderator
19:00-19:05	Opening	柯道維 醫師 中國附醫	
19:05-19:45	Post ASCO update – Precision medicine for metastatic CRC	陳敬左 醫師 新竹台大	柯道維 醫師 中國附醫
19:45-20:15	Trial experience and real-world adoption of mCRC precision treatment	徐鴻智 醫師 林口長庚	蔣鋒帆 醫師 臺中榮總
20:15-20:30	Q&A , Closing	蔣鋒帆 醫師 臺中榮總	

僅供受邀醫事人員參與 ① 醫事人員繼續教育學分申請中：中華民國大腸直腸外科醫學會、中華民國癌症醫學會

 註冊線上會議

 Add to Calendar

主辦單位



中華民國大腸直腸外科醫學會
SOCIETY OF COLON AND RECTAL SURGEONS, Taiwan

贊助單位

AMGEN

台灣安進藥品有限公司

台北市信義區松仁路100號13樓之1
TEL: (02) 2544-2888 FAX: (02) 2713-5781
www.amgen.com.tw

Curriculum Vitae

Ching-Tso, Chen

Department of Oncology, National Taiwan University Hospital Hsinchu Branch
No. 25, Ln. 442, Sec. 1, Jingguo Rd., East Dist., Hsinchu City 30059 , Taiwan
(+886)2-23123456 #52481 robarroyce@gmail.com
Date of Birth: April 25th, 1988



Education

Taipei Medical University, Department of Medicine	2006 - 2013
---	-------------

Work Experience

Medical oncologist, Department of Oncology, National Taiwan University Hospital Hsinchu Branch	2021 - Present
Fellowship, Department of Oncology, National Taiwan University Hospital	2018 - 2021
Resident, Department of Internal Medicine, National Taiwan University Hospital	2016 - 2018
Post-graduate year resident, National Taiwan University Hospital	2015 - 2016
Intern, National Taiwan University Hospital	2013 - 2014

Summary of qualification

Board of Medical Oncology	2020-
Board of Internal Medicine	2018-

Professional Membership

Taiwan Liver Cancer Association (TLCA)	2023-
Taiwan Oncology Society (TOS)	2018-
Society of Internal Medicine of Taiwan (R.O.C.)	2016-

Honors

ESMO Asia Poster Presentation Merit Award	2019
TJCC Poster Presentation Excellence Award	2024

Publication:

Referred paper:

1. Ching-Tso Chen, Jen-Chieh Lee, Shih-Chiang Huang, Tom Wei-Wu Chen. Dacarbazine and Bevacizumab Improved Paraneoplastic Doege-Potter Syndrome of Malignant Solitary Fibrous Tumor. Journal of Cancer Research and Practice 2021;8:68-72
2. Ching-Tso Chen, Tsung-Hao Liu, Yu-Yun Shao, Kao-Lang Liu, Po-Chin Liang, Zhong-Zhe Lin. Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences 2021 Nov 28;22(23):12880.
3. Ching-Tso Chen, Yin-Hsun Feng, Chia-Jui Yen, San-Chi Chen, Yun-Tzu Lin, Li-Chun Lu, Chih-Hung Hsu, Ann-Lii Cheng, Yu-Yun Shao. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatology International 2022 Oct;16(5):1199-1207.
4. Ching-Tso Chen, Chih-Hung Hsu, Ann-Lii Cheng, Yu-Yun Shao. Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study. Anticancer Research September 2022, 42 (9) 4461-4470.
5. Ching-Tso Chen, Yi-Hsin Liang, Chien-Wen Hung, Kun-Huei Yeh. Multiple immunosuppressants for immune-related acholia in a patient with metastatic colorectal cancer. Journal of Cancer Research and Practice 2023;10:38-43.
6. Ching-Tso Chen, Hsing-Wu Chen, Wei-Hsin Lin, Pei-Ming Huang, Mong-Wei Lin, Ching-Yao Yang, Che-Yu Hsu, Chia-Chun Wang, Jen-Chieh Lee, Koping Chang, Kuo-Hao Huang, Ho-Min Chen, Tom Wei-Wu Chen, Rong-Sen Yang, Ruey-Long Hong. Sequential multimodal treatments with chemotherapy and surgery for advanced soft

tissue sarcoma may be associated with better survival than chemotherapy. Journal of the Formosan Medical Association. <https://doi.org/10.1016/j.jfma.2024.03.007>

Abstract

1. Ching-Tso Chen, Tom Wei-Wu Chen, Hsing-Wu Chen, et al. Focal treatments for metastatic soft tissue sarcoma (mSTS) are associated with improved overall survival. ESMO Asia 2019 . (Merit Award)
2. Ching-Tso Chen, Yin-Hsun Feng, Chia-Jui Yen, et al. Prognosis and Second-Line Treatment Outcome of Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab and Bevacizumab Treatment. APPLE 2021 .
3. Ching-Tso Chen, Yu-Yun Shao, Hung-Wei Hsu, Rita R. Wo, Han-Yu Wang, Ann-Lii Cheng, Chih-Hung Hsu. Abstract 5985: Cyclin dependent kinase 9 (CDK9) inhibition increased efficacy of programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma (HCC) through decreasing programmed death-ligand 1 (PD-L1) expression. AACR 2023
4. Choong-kun Lee, Changhoon Yoo, ... Ching-Tso Chen, ... et al. Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries. Abstract 970P. ESMO 2023
5. Ching-Tso Chen, Yi-Hsin Liang, Kun-Huei Yeh. Trifluridine/tipiracil (TAS-102) in combination with anti-EGFR re-challenge versus TAS-102 plus anti-VEGF in patients with mCRC who experienced first-line anti-EGFR-based chemotherapy. ASCO GI 2024
6. Yu-Yun Shao, Ching Tso Chen, Tsung-Che WuT, Tsung-Hao Liu, Chien-Huai Chuang, Ann-Lii Cheng, Chih-Hung Hsu. Safety of prompt initiation of durvalumab or STRIDE (single tremelimumab regular interval durvalumab) regimen as hepatocellular carcinoma (HCC) treatment for patients with chronic active hepatitis B. AACR 2024
7. Ching-Tso Chen, Chien-Huai Chuang, Chih-Hung Hsu, Yu-Yun Shao. Early PIVKA-II response predictive of treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. TJCC 2024
8. Ching-Tso Chen. Locoregional therapy combinations for advanced hepatocellular carcinoma after Atezolizumab and Bevacizumab. KSMO 2024.

Curriculum Vitae

Name: Hsu, Hung - Chih

Sex: male

Birth Date: 04/Jul/1972

Birth Place: Taichung City, Taiwan

Citizenship: Republic of China, Taiwan

Office Address & TEL NO.:

Address: No.5, Fusing St., Gueishan Township, Taoyuan County 333, Taiwan

TEL NO: 88633281200-8825

Language: Chinese, English, Taiwanese

Education:

1. 01/ Sep/1991~30/Jun/1998: Medical department, Taipei Medicine University, Taipei City, Taiwan
2. Sep/2008~Oct/2014: Chang Gung University, Graduate institute Clinical medicine, Ph.D

Academic Appointment (Include Teaching Experience):

1. Research Experience: From Feb 2007 to Jan 2008, research fellow in UC Davis Medical cancer center Basic science Department, USA.
2. Academic Teaching Rank Accreditation Certificate Assistant Professor (01/Aug/2018~)

Employment Record:

1. Resident: 01/Aug/2000~30/Jun/2003, Department of Internal Medicine, Chang Gung Memorial Hospital, Taiwan.
2. Fellow: 01/Jul/2003~30/Jun/2006, Division of Hematology/Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taiwan.
3. Attending physician and associate professor, Division of Hematology/Oncology

Board Certification:

2004 Board of Internal Medicine, Republic of China. [內專醫字第 006686 號]

2005 Board of Chinese Oncology, Republic of China [中腫內專醫證字第 94014 號]

2018 Academic Teaching Rank Accreditation Certificate Assistant Professor [助理字第 147263 號]

Licensers:

Licensers Chinese License NO 醫字第 029847 號

Professional Affiliations:

1. Taiwan Society of Internal Medicine
2. The Taiwan Oncology Society(TOS)
3. The Hematology Society of Taiwan

Affiliation position:

Deputy Secretary-General of Taiwan Oncology Society(2023/5/12~2024/05/11)

Research interest:

1. Tumor immunology
2. Molecular oncology
3. Colorectal cancer
4. Clinical trial design

Research Project :

1. The role of Lgr5 in prognosis and tumorigenesis of colorectal cancer
(CMRPG380891, PI, 01/Jul/2009~30/Jun/2010)
2. Using a New Tool to Isolate Circulating Tumor Cells with Magnet Beads and Compare with Clinical Outcomes
(IRB101-2161C(原 99-4095B), PI, 04/Mar/2011~31/Dec/2015)
3. The role of Lysine specific demethylase 1 (LSD1) in tumorigenesis and prognosis of colorectal cancer
(CMRPG3B1361, PI, 01/Sep/2012~31/Aug/2013)
4. Molecular biomarker in anti-EGFR therapy and its resistance mechanism for metastatic colorectal cancer
(CMRPG3C1841, PI, 1/Nov/2013-31/Apr/2014)
5. CMRPG3C1561, co-PI, 1/Sep/2013-31/Aug/2014)
6. The Incidence, Severity, Pattern of Change, and Predicting Factors of Acute and Chronic Peripheral Neuropathy, and Effects of Education and Exercise Program for Colorectal Cancer Patients with Oxaliplatin-Induced Peripheral Neuropathy (OXAIPN): A Longitudinal Study
(MOST 104-2314-B-255 -007 -MY3, co-PI, 1/Aug/2015- 31/Dec/2018)
7. T cell receptor in colorectal cancer
(CORPG3F0061-0063 , co-PI, 1/Apr/2016-31/Mar/2019)
8. Using Next Generation Sequencing to detect circulating tumor DNA for prediction of therapy resistance / prognosis in and elucidation of cancer related genes status in colorectal cancer patients
(IRB 201600209B0, PI, 26/Apr/2016~25/Apr/2019)
9. Clinical Relevance of Next-generation Sequencing Analysis for High-purity Circulating Tumor Cells from Cancer Patients with Disruptive Gene Mutation(s)
(MOST 105-2314-B-182A-030-, co-PI, 1/Aug/2016- 31/Dec/2017)
10. CMRPG3G1591, co-PI , 1/Nov/2017~31/Oct/2018

11. Using CGRD for analysis of factors related to treatment outcome and prognosis in colorectal cancer patients and establish prognostic model
(CORPG3F0901, PI, 1/Dec/2016-30/Sep/2018)
12. Using next generation high-throughput sequencing to detect circulating exosomal microRNA for predicting therapy resistance /prognosis and elucidating drug resistance mechanism in metastatic colorectal cancer patients
(CORPG3F0061-0063, co-PI, 1/Dec/2016-31/Nov/2017)
13. Investigation of immune mediators and clinical correlations in oxaliplatin-induced hypersensitivity reactions
(CMRPG3G2071, PI, 1/Dec/2017-30/Nov/2018)
14. To elucidate the role of circulating exosomal miRNA in metastatic colorectal cancer during therapy via next generation sequencing
(CORPG3F0061-0063, PI, 1/Dec/2017-31/Nov/2018)
15. Investigation of the microbiota and its correlation with clinical features, molecular factors, and prognosis in metastatic colorectal cancer
(MOST 107-2314-B-182A-024-, PI, 1/Aug/2018- 31/Jul/2019)
16. Using next generation high-throughput sequencing to analyze and characterize T cell receptor repertoire of metastatic colorectal cancer patients for predicting therapy resistance /prognosis and elucidating its related immune mechanism
(CMRPG3I0311, PI, 1/Jan/2019-31/Dec/2019)
17. Investigation of immune mediators and clinical correlations in oxaliplatin- induced hypersensitivity reactions
(NMRPG3J0101, PI, 1/Aug/2019- 31/Jul/2020)
18. Development of genetic biomarker panel for predicting prognosis and monitoring treatment efficacy in colorectal cancer
(CMRPG3I0311, PI, 1/Sep/2020-31/Aug/2022)
19. Investigation of the correlated effect of microbiota changes and T cell receptor in the tumor microenvironment of metastatic colorectal cancer patients on tumor mutational burden and prognosis
(NMRPG3L0341, 110-2314-B-182A-094-, PI, 2021/08/01~2022/07/31)

20. Investigation of the correlation between Immune cell type of tumor microenvironment, T cell receptor and treatment response/prognosis in metastatic colorectal cancer
(CMRPG3K2201, PI, 1/Jan/2021~31/Dec/2022)
21. To investigate the role of lncRNA (Lnc-FZD5-2) in prognosis, tumorigenesis and drug resistance of colorectal cancer
(NMRPG3M0341, 111-2314-B-182A-120 -, PI, 1/Aug/2022~31/Jul/2023)
22. To investigate the correlation of genetic alteration, tumor microenvironment, clinicopathologic factors, and prognosis for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer patients
(CMRPG3N0531, PI, 1/Jul/2023~30/Jun/2025)
23. Preparation of autologous tumor infiltrating lymphocytes for treating patients with solid tumors
(CSRPG3N0011, PI, 1/Jul/2023~30/Jun/2025)

Bibliography:

1. Publications:

2014~2021

- (1). Kuo YC, Liu HT, Lin YL, Yang YC, Yang TS, Liao CT, Shen WC, Hsu HC, Chou WC, Chen JS*. Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: A retrospective analysis from a medical center. Biomed J. 2014 May-Jun;37(3):141-6. (2017 SCI ; IF=1.723; BIOCHEMISTRY&MOLECULAR BIOLOGY 235/293)
- (2). Hung YS, Chou WC, Chen TD, Chen TC, Wang PN, Chang H, Hsu HC, Shen WC, Cheng WH, Chen JS*. Prognostic factors in adult patients with solid cancers and bone marrow metastases. Asian Pac J Cancer Prev. 2014;15 (1):61-7. (2014 SCI: IF=2.514; ONCOLOGY 120/211)
- (3). Kao CY, Wang HM, Tang SC, Huang KG, Jaing TH, Liu CY, Liu KH, Shen WC, Wu JH, Hung YS, Hsu HC, Chen JS, Liao CT, Lin YC, Su PJ, Hsieh CH, Chou WC*. Predictive factors for do-not-resuscitate designation among terminally ill cancer patients receiving care from a palliative care consultation service. J Pain

Symptom Manage. 2014 Feb;47(2):271-82. (2017 SCI ; IF=3.249; MEDICINE, GENERAL & INTERNAL 29/155)

- (4). **Hsu HC**, Liu YS, Tseng KC, Tan BC, Chen SJ, Chen HC*. LGR5 regulates survival through mitochondria-mediated apoptosis and by targeting the Wnt/ β -catenin signaling pathway in colorectal cancer cells. Cell Signal. 2014 Nov;26(11):2333-42. (2017 SCI ; IF=3.487 ; CELL BIOLOGY 90/190)
- (5). Huang WK, Kuo YC, Tsang NM, **Hsu HC**, Shen WC, Chou WC, Yang TS, Chen JS*. Concurrent Chemoradiotherapy with or without Induction Chemotherapy versus Chemotherapy Alone in Patients with Locally Advanced Pancreatic Cancer. Anticancer Res. 2014 Nov;34(11):6755-61. (2017 SCI ; IF=1.865 ; ONCOLOGY 183/223)
- (6). **Hsu HC**, Liu YS, Tseng KC, Yang TS, Yeh CY, You JF, Hung HY, Chen SJ, Chen HC*. CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression. J Cancer Res Clin Oncol. 2015 Jan;141(1):11-21.(2017 SCI ; IF=3.28 ; ONCOLOGY 108/223)
- (7). Huang CY, Lu CH, Yang CK, **Hsu HC**, Kuo YC, Huang WK, Chen JS, Lin YC, Chia-Yen H, Shen WC, Chang PH, Yeh KY, Hung YS, Chou WC*. A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin. Medicine (Baltimore). 2015 Nov;94(47): e2135. (2017 SCI ; IF=2.028 ; MEDICINE, GENERAL & INTERNAL 29/155)
- (8). Huang WK, **Hsu HC**, Liu JR, Yang TS, Chen JS, Chang JW, Lin YC, Yu KH, Kuo CF, See LC*. The Association of Ursodeoxycholic Acid Use With Colorectal Cancer Risk: A Nationwide Cohort Study. Medicine (Baltimore). 2016 Mar;95(11):e2980. (2017 SCI ; IF=2.028 ; MEDICINE, GENERAL & INTERNAL 29/155)
- (9). **Hsu HC**, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, Chen SJ, Yang TS*. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget. 2016 Apr 19;7(16):22257-70. (2016 SCI ; IF=5.168 ; ONCOLOGY 44/217)

- (10). Lai BR, Wu YT, Kuo YC, **Hsu HC**, Chen JS, Chen TC, Wu RC, Chiu CT, Yeh CN, Yeh TS*. Targeted ultra-deep sequencing unveils a lack of driver-gene mutations linking non-hereditary gastrointestinal stromal tumors and highly prevalent second primary malignancies: random or nonrandom, that is the question. *Oncotarget*. 2016 Dec 13;7(50):83270-83277. (2016 SCI ; IF=5.168 ; ONCOLOGY 44/217)
- (11). Chou WC, Wu MH, Chang PH, **Hsu HC**, Chang GJ, Huang WK, Wu CE, Hsieh JC*. A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer. *Int J Biol Sci*. 2018 Jan 12;14(2):137-146. (2017 SCI ; IF=4.057 ; BIOCHEMISTRY&MOLECULAR BIOLOGY 72/293)
- (12). **Hsu HC**, Lapke N, Chen SJ, Lu YJ, Jhou RS, Yeh CY, Tsai WS, Hung HY, Hsieh JC, Yang TS, Thiam TK, You JF*. PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients. *Cancers (Basel)*. 2018 Sep 6;10(9). pii: E314. (2017 SCI ; IF=5.326 ; ONCOLOGY 45/223)
- (13). **Hsu HC**, Lapke N, Wang CW, Lin PY, You JF, Yeh CY, Tsai WS, Hung HY, Chiang SF, Chen HC, Chen SJ, Hsu A, Yang TS*. Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer. *Mol Cancer Ther*. 2018 Oct;17(10):2238-2247. (2017 SCI ; IF=5.365 ; ONCOLOGY 43/223)
- (14). TH Chen, CM Hsu, **HC Hsu**, CT Chiu, MY Su, YY Chu, ML Chang*. Plasminogen activator inhibitor-1 is associated with the metabolism and development of advanced colonic polyps *Transl Res*. 2018 Oct;200:43-53. (2017 SCI ; IF=4.880 ; LABORATORY TECHNOLOGY & INTERNAL 3/30)
- (15). **Hsu HC**, Chou WC, Kuan FC, Lee KD, Rau KM, Huang JS, Yang TS. A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients. *Cancer Manag Res*. 2018 Nov 21;10:6061-6070
- (16). Lai HL, Chen YY, Lu CH, Hung CY, Kuo YC, Chen JS, **Hsu HC**, Chen PT, Chang PH, Hung YS, Chou WC. Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational

cohort study in Taiwan. *Cancer Med.* 2019 May;8(5):2085-2094.

- (17). **Hsu HC**, Liu YC, Wang CW, Chou WC, Hsu YJ, Chiang JM, Lin YC, Yang TS. Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer. *Cancer Med.* 2019 Jul;8(7):3437-3446.
- (18). Lee SH, Chang PH, Chen PT, Lu CH, Hung YS, Tsang NM, Hung CY, Chen JS, **Hsu HC**, Chen YY, Chou WC. Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. *Cancer Med.* 2019 Jul;8 (7): 3471-3478.
- (19). **Hsu HC**, You JF, Chen SJ, Chen HC, Yeh CY, Tsai WS, Hung HY, Yang TS, Lapke N, Tan KT. TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer. *Cancers (Basel).* 2019 Jul 30;11(8). pii: E1079.
- (20). PhD thesis: The role of Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) in colorectal cancer pathogenesis, 2014
- (21). Chiang TY, **Hsu HC**, Jane SW, Chen SC. (2020, Oct). EGFR-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy. *supportive care in cancer*.
- (22). Huang WK, Chang SH, **Hsu HC**, Chou WC, Yang TS, Chen JS, Chang JW, Lin YC, Kuo CF, See LC (2020, Oct). Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study.. *international journal of cancer*.
- (23). Huang WK, **Hsu HC**, Chang SH, Chou WC, Chang PH, Chiang SF, Chang JW, Chen JS, Yang TS, See LC. (2021, Jun). Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis.. *Frontiers in pharmacology*.
- (24). **Hsu HC**, Huang KC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang TS, Chen CC, Chao Y,

- Teng HW. (2021, Jul). Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread. *Scientific Reports*
- (25). Su YL, Tsai KL, Chiu TJ, Lin YM, Lee KC, Lu CC, Chen HH, Wu CC, **Hsu HC** (2021, Oct). Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment.. *Cancers (Basel)*.
- (26). Chen HH, Ke TW, Huang CW, Jiang JK, Chen CC, Hsieh YY, Teng HW, Lin BW, Liang YH, Su YL, **Hsu HC**, Kuan FC, Chou YH, Lin J, Lin BR, Chang YY, Wang JY. (2021, Nov). Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment.. *Frontiers in Oncology*.
- (27). **Hung-Chih Hsu**(co-first author), Yi-Tung Chen, Yun-Shien Lee, Hsuan Liu6, Bertrand Chin- Ming Tan, hia-Yin Chin, Ian Yi-Feng Chang, Chia-Yu Yang (2021, Dec). Longitudinal high-throughput sequencing of the T-cell receptor repertoire reveals dynamic change and prognostic significance of peripheral blood TCR diversity in metastatic colorectal cancer during chemotherapy. *Frontiers in immunology*.
- (28). Yang CK, **Hsu HC**, Liu YH, Tsai WS, Ma CP, Chen YT, Tan BC, Lai YY, Chang IY, Yang C, Yang CY, Yu JS, Liu H. (2022, Aug). EV-miRome-wide profiling uncovers miR-320c for detecting metastatic colorectal cancer and monitoring the therapeutic response. *Cell Oncol (Dordr)*.
- (29). Huang WK, Ho WP, **Hsu HC**, Chang SH, Chen DY, Chou WC, Chang PH, Chen JS, Yang TS, See LC. (2022, Aug). Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer. *Front Cardiovasc Med*.
- (30). You JF, Hsu YJ, Chern YJ, Cheng CC, Jong BK, Liao CK, Hsieh PS, **Hsu HC**, Tsai WS. (2022, Dec) Preoperative Cancer Inflammation Prognostic Index as a Superior Predictor of Short- and Long-Term Outcomes in Patients with Stage I-III Colorectal Cancer after Curative Surgery. *Cancers (Basel)*.
- (31). Hung CL, Liu HH, Fu CW, Yeh HH, Hu TL, Kuo ZK, Lin YC, Jhang MR, Hwang CS, **Hsu HC**, Kung HJ, Wang LY. (2023, May). Targeting androgen

receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer. *EBioMedicine*.

- (32). Chiang TY, **Hsu HC**, Chern YJ, Liao CK, Hsu YJ, Tsai WS, Hsieh PS, Lin YF, Lee HL, You JF. (2023, Mar). Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy? *Cancers (Basel)*.
- (33). Wang IY, Jane SW, **Hsu HC**, Lin YC, Tsai WS, Young CY, Beaton RD, Huang HP. (2023, Apr). The Longitudinal Trends of Care Needs, Psychological Distress, and Quality of Life and Related Predictors in Taiwanese Colorectal Cancer Survivors. *Semin Oncol Nurs*.
- (34). Chang YT, Chen CC, Chang SC, Chang YY, Lin BW, Chen HH, Hsieh YY, **Hsu HC**, Hsieh MC, Kuan FC, Wu CC, Lu WC, Su YL, Liang YH, Chen JB, Huang SY, Huang CW, Wang JY. (2023, Jun). Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study. *Nutrients*.
- (35). Huang WK, **Hsu HC**, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. (2023, Sep). Zinc supplementation decreased incidence of grade ≥ 2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. *J Am Acad Dermatol*.
- (36). Huang WK, **Hsu HC**, Yang TS, Lu CW, Pan YR, Wu CE, Chung WH, Hung SI, Yeh CN. (2023, Dec). Zinc supplementation decreased incidence of grade ≥ 2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. *Eur J Cancer*.
- (37). Hung SI, Chu MT, Hou MM, Lee YS, Yang CK, Chu SY, Liu FY, **Hsu HC**, Pao SC, Teng YC, Chen CB, Chao A, Chung WH, Chang JW, Lai CH. (2023, Dec). Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer. *Biomed Pharmacother*.
- (38). Chen CC, Chang SC, Chang YY, Lin BW, Chen HH, Hsieh YY, Hsu HC, Hsieh MC, Ke

TW, Kuan FC, Wu CC, Lu WC, Su YL, Liang YH, Chen JB, Huang HY, Tsai HL, Wang JY. (2023, Dec). Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry. *Am J Cancer Res*.

(39). Chiang TY, Hsu YJ, Chern YJ, Liao CK, Tsai WS, Hsieh PS, **Hsu HC**, Lin YF, Lee HL, You JF. (2024, Feb). Association between personality types and low anterior resection syndrome in rectal cancer patients following surgery. *Cancer Med*.

(40). Lu CW, Yeh CN, **Hsu HC**, Chen CB, Yang TS, Pan YR, Chung WH, Hung SI. Zinc supplementation is associated with improvement in hand-foot skin reaction in patients on vascular endothelial growth factor receptor-tyrosine kinase inhibitors: A cohort study. (2024, Apr). *J Am Acad Dermatol*.

(41). **Hsu HC**, Chung WH, Lin YC, Yang TS, Chang JW, Hsieh CH, Hung SI, Lu CW, Chen JS, Chou WC, Wang CW. (2024, Apr). Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions. *Allergol Int*

2007~2013

(1). Chou WC, Lu CH, Lin G, Hong YS, Chen PT, **Hsu HC**, Chen JS, Yeh KY, Wang HM, Liaw CC. Transcutaneous arterial embolization to control massive tumor bleeding in head and neck cancer: 63 patients' experiences from a single medical center. *Support Care Cancer*. 2007 Oct;15(10):1185-90. (2017 SCI ; IF=2.676 ; REHABILATION 12/65)

(2). **Hsu HC**, Chang HK, Lin YC, Hseu S, Chen JS, Yang TS, Wang HM, Shen WC. The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. *Chang Gung Med J*. 2009 Jan-Feb;32(1):33-41. (2017 SCI ; IF=1.723; BIOCHEMISTRY&MOLECULAR BIOLOGY 235/293)

(3). Shen WC, Yang TS, **Hsu HC**, Chen JS*. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer. *Chang Gung Med J*. 2011 Nov-Dec; 34(6):590-8. (2017 SCI ; IF=1.723; BIOCHEMISTRY&MOLECULAR

BIOLOGY 235/293)

(4). Chen JS, Chen YY, Huang JS, Yeh KY, Chen PT, Shen WC, **Hsu HC**, Lin YC, Wang HM*. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric Cancer. 2012 Jan; 15(1):49-55. (2017 SCI ; IF=5.045 ; GASTROENTEROLOGY & HEPATOLOGY 13/80)

(5). Wu CE, **Hsu HC**, Shen WC, Lin YC, Wang HM, Chang JW, Chen JS*. Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: a retrospective analysis. Chang Gung Med J. 2012 Sep-Oct; 35(5):420-7. (2017 SCI ; IF=1.723; BIOCHEMISTRY&MOLECULAR BIOLOGY 235/293)

(6). Lin HC, **Hsu HC (equal first author)**, Hsieh CH, Wang HM, Huang CY, Wu MH, Tseng CP*. A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clin Chim Acta. 2013 Apr 18; 419: 77-84. (2017 SCI ; IF=2.926 ; MEDICAL LABORATORY TECHNOLOGY 8/30)

(7). **Hsu HC**, Chou WC, Shen WC, Wu CE, Chen JS, Liao CT, Lin YC; Yang TS*. Efficacy of Postoperative Oxaliplatin- or Irinotecan-based Chemotherapy after Curative Resection of Synchronous Liver Metastases from Colorectal Cancer. Anticancer Res. 2013 Aug; 33(8):3317-25. (2017 SCI ; IF=1.865 ; ONCOLOGY 183/223)

(8). Liu YS, **Hsu HC (equal first author)**, Tseng KC, Chen HC*, Chen SJ*. Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer. Biomedicine & Pharmacotherapy 2013 Oct;67(8):791-9. (2017 SCI ; IF=3.457 ; PHARMACOLOGY & PHARMACY 69/261)

(9). **Hsu HC**, Liu YS, Tseng KC, Hsu CL, Liang Y, Yang TS, Chen JS, Tang RP, Chen SJ*, Chen HC*. Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. Int J Colorectal Dis. 2013 Nov;28(11):1535-46 (2017 SCI ; IF=2.533 ; SURGERY 62/200)

(10). Chou WC, Chang CL, Liu KH, Hsu JT, Cheng WH, **Hsu HC**, Shen WC, Hung YS, Chen JS*. Total gastrectomy increases the incidence of grade III and

IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment.
World J Surg Oncol. 2013 Nov 1;11:287. (2017 SCI ; IF=1.792 ; SURGERY
101/200)

2. Presentations: Poster

- (1). Intermittent Fever Pattern, Together With Pulse Rate Monitoring, and Finally Naproxen Test Improves the Safety to Identify Neoplastic Fever from Solid Tumors, The 9th Taiwan Joint Cancer Conference , Taipei, Taiwan
- (2). Incidence of chemotherapy induced nausea and vomiting in Taiwan : perception versus reality, The 9th Taiwan Joint Cancer Conference , Taipei, Taiwan
- (3). A combined mutation signature analysis of KRAS, NRAS and BRAF by next generation sequencing improves cetuximab treatment prediction in metastatic colorectal cancer, The 20th Taiwan Joint Cancer Conference, Taipei, Taiwan
- (4). A phase II trial of S-1 plus Calcium folinate in heavily pretreated metastatic colorectal cancer patients, The 21th Taiwan Joint Cancer Conference, Taipei, Taiwan
- (5). Loss of function in metastatic colorectal cancer patients PTPRT and PTPRD mutations predict bevacizumab resistance metastatic colorectal cancer patients, The 2016 ESMO Asia Congress Singapore.
- (6). Circulating tumor DNA as a dynamic marker for disease burden in patients with metastatic colorectal cancer, The 2016 ESMO Asia Congress Singapore.

3. Presentation: Speech

- (1). **2016/12/10~2016/12/11 Society of Colon and Rectal Surgeons, Taiwan**
演講題目: Addressing Complexities Along the Metastatic Colorectal Cancer Care Continuum
- (2). **2017/4/6 Taiwan Precision Medicine Society Liquid biopsy workshop**
演講題目: Use of circulating tumor DNA as a dynamic marker for disease status in metastatic colorectal cancer patients
- (3). **2017/7/23 Taiwan Oncology Society Best of 2017 ASCO Meeting**
演講題目: At the forefront of progress: Latest advances in mCRC

- (4). 2017/12/17 海峽腫瘤高峰論壇**
演講題目: 台灣結直腸癌規範化治療亮點
- (5). 2018/7/15 Taiwan Oncology Society Best of 2018 ASCO Meeting**
演講題目: The evolving landscape in the management of mCRC
- (6). 2020/7/18 台灣臨床藥學會 癌症免疫治療-從基礎到應用-系列課程 5**
演講題目: Immunotherapy in Colorectal Cancer
- (7). 2021/5/7 台灣精策會 精準醫療:技術、政策、法規與臨床應用**
演講題目: 轉移性直腸癌患者動態生物標誌之運用-循環腫瘤 DNA
- (8). 2021/11/27 18th Congress of Asia Pacific Federation of Coloproctology (APFCP)**
演講題目: Precision Medicine in Colorectal Cancer: Research and Clinical Practice
- (9). 2022/07/16 202 中華民國癌症醫學會 summit summer session**
演講題目: Novel therapeutic strategies of colorectal cancer treatment
- (10). 2023/07/16 2023 中華民國癌症醫學會 summit summer session**
演講題目: Comprehensive review of 3rd-4th line treatment for advanced CRC
- (11). 2023/12/16 中華民國大腸直腸外科醫學會年會**
演講題目: Recent Breakthroughs in Treating BRAF V600E Mutant Colorectal Cancer